Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the Clinical Director of the Genitourinary Cancers Program at University of Washington and Seattle Cancer Care Alliance. He is an Associate Professor in the Dept. of Medicine, Division of Medical Oncology. He is an Associate Member at the Fred Hutchinson Cancer Research Center. He started on those positions in January 2018. Dr. Grivas completed his training at the University of Patras Medical School and took his M.D. degree in 2005; he then pursued Ph.D. in Medical Oncology under the mentorship of key academic faculty and defended his thesis successfully in late 2008. He completed his Residency in Internal Medicine at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia, USA) in 2010. He then completed his Fellowship in Hematology/Oncology at University of Michigan (Ann Arbor, USA) in 2013. He stayed there as Clinical Lecturer for another year before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland, USA), where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, teaching and mentoring trainees, and seeing patients with GU cancers. He has had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer (e.g. avelumab switch maintenance based on Javelin Bladder100, sacituzumab govitecan based on TROPHY-U-01), and is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading large innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to efficient, personalized, and outstanding patient care and believes in optimal patient-physician relationship as well as community outreach.